Visiongain Publishes Adrenocorticotropic Hormone (ACTH) Market Report 2021-2031

11 November 2020

Visiongain has published a new report on Adrenocorticotropic Hormone (ACTH) Market Report 2021-2031: Forecasts By Type (AQB-565, BIM-23B065, Corticotropin, Others, By Product (Natural, and Synthetic), By Indication (Nephrotic Syndrome, Ophthalmology, Rheumatology, Addison Disease, Cushing Syndrome, Cushing Disease, and Others), By Age Group (Adult, and Children), By End-User (Hospitals, Specialty Clinics, Academics and Research Institute, and Others), By Distribution Channel (Hospital Pharmacy, and Retail Pharmacy, and Online Pharmacy). PLUS Profiles of Leading Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.

Global Adrenocorticotropic Hormone (ACTH) market was valued at US$ xx Million in 2019 and is projected to reach at a market value of US$ xx Million by 2031. North America dominated the global Adrenocorticotropic Hormone (ACTH) market and is projected to witness CAGR of XX% during the first half of the forecast period i.e. 2021 to 2031.

COVID-19 Impact on Adrenocorticotropic Hormone (ACTH) Market
COVID-19 impact through different recovery models such as V-shaped, U-shaped, W-shaped, and L-shaped; has been taken into consideration while estimating and forecasting the Adrenocorticotropic Hormone (ACTH) market. Different recovery scenarios are also included in the report for all the segments and regions/nation. The recovery scenarios based on which market has been forecasted and analysed herein the report are mentioned below:

Market Drivers

Increasing usage of Adrenocorticotropic Hormone products
The application of adrenocorticotropic hormone (ACTH) has increased very significantly over the past few years. Currently, the adrenocorticotropic hormone is administered for the treatment of nephrotic syndrome, ophthalmology, rheumatology, Addison disease, Cushing syndrome, Cushing disease, and others. The increase in the usage of adrenocorticotropic hormone products is creating a huge demand for the adrenocorticotropic hormone (ACTH) products and working as a driver for the market.

Market Opportunities

Government initiative and awareness program
Governments in various developed and developing nations are increasing their initiatives to increasing awareness regarding the availability of treatment for nephrotic syndrome, ophthalmology, rheumatology, Addison disease, Cushing syndrome, Cushing disease, and others. Further, Governments and private authority across the developed & developing countries are focusing on the increasing number of new approval for adrenocorticotropic hormone (ACTH) which will help to create new opportunities for the market.

Technological Advancements and the modernization in Adrenocorticotropic Hormone (ACTH)
Researchers and manufacturers from all over the world are increasing research and development activates for the development of new, innovative, more effective, economic and to increase the clinical application of adrenocorticotropic hormone (ACTH). New research and development will lead to the introduction of new products in the market which is expected to increase the adoption of adrenocorticotropic hormone (ACTH).

Competitive Landscape
Top companies (Mallinckrodt, Pfizer, Novartis AG,) constitute more than XX% share of the global Adrenocorticotropic Hormone (ACTH) market. Other companies profiled in the report include Mylan N.V., and Hikma Pharmaceuticals others Some of the key developments are listed below:

• In 2018, Mallinckrodt ARD Inc. has received U.S. FDA approval for H.P. Acthar Ge. H.P. Acthar Ge is an adrenocorticotropic hormone (ACTH) analog indicated as monotherapy for infantile spasms treatment in infants. Through this development company will widen its market-focused product portfolio.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021


Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021


Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021


Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2021-2031

Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.

12 July 2021